TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...
TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ... TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...
2B.3 Karageorgopoulos DE et al. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8:751-62. 2B.4 Zavascki AP et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71-93. 2A.5 Perez F et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84. 2B.6 Munoz-Price LS et al. Acinetobacter infection. N Engl J Med 2008;358:1271-81. 2B.7 Gootz TD et al. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ther 2008;6:309-325. 2B.8 Maragakis LL et al. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254-63. 2B.9 Appleman MD et al. In vitro activities of non traditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 2000;44:1035-40. 2B.10 Murray CK et al. Treatment of multidrug resistant Acinetobacter. Curr Opin Infect Dis 2005;18:502- 6. 2B.11 Fournier PE et al. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-9. 2B.12 Sengstock DM et al. Multidrug‐resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 2010;50:1611-6. 2B.13 Yoon J et al. In vitro double and triple synergistic activities of polymyxin B, imipenem and rifampin against multidrug resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:753- 7. 2B.14 Roberts JA et al. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007;30:11-8. 2B.15 Gordon NC et al. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009;63:775-80. 2B.16 Moland ES et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother 2008;52:2940-2. 2B.17 Scheetz MH et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:1621-6. 2B.18 Karageorgopoulos DE et al. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008;62:45-55. 2B.19 Anthony KB et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70. 2B.20 Peleg AY et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31. 2B.21 Capone AJ et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2008;62:422-5. 2B.22 Navon-Venezia S et al. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;59:772-4. 2B.23 Bassetti M et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417-20. 2B.24 Garnacho-Montero J et al. Treatment of multidrug resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem susceptible VAP. Clin Infect Dis 2003;36:1111-8. 2B.25 Levin AS et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11. 2B.26 Falagas ME et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35:194-9. 2B.27 Li J et al. Colistin: the re-emerging antibiotic for multidrug-resistant, Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601. 2B.28 Falagas ME et al. Colistin: the revival of polymyxins for the management of multidrug-resistant Gramnegative bacterial infections. Clin Infect Dis 2005;40:1333-41. 2B.29 Falagas ME et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009;34:111-20. 2B.30 Drapeau CM et al. Rifampicin combined regimens for Gram-negative infections: data from the literature. Int J Antimicrob Agents 2010;35:39-44. 2B.31 Plachouras D et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6. 2B.32 Giske CG et al. Redefining extended-spectrum β-lactamases: balancing science and clinical need. J Antimicrob Chemother 2009;63:1-4. 2B.33 Roberts JA et al. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007;30:11-8. 2B.34 Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010;70:313-33. 2B.35 Glupczynski Y et al. In vitro activity of temocillin against prevalent extended spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 2007;26:777-83. 2B.36 Castanheira M et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008;52: 570-3. 2B.37 Arias CA et al. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008;6:637-55. 2B.38 Gavaldà J et al. Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007;146:574-9.
2B.39 Cookson BD et al. Guidelines for the control of glycopeptide resistant enterococci in hospitals. J Hosp Infect 2006;62:6-21. 2B.40 Zirakzadeh A et al. Vancomycin resistant enterococci: colonization, infection, detection and treatment. Mayo Clin Proc 2006;81:529-36. 2B.41 Murray BE. Vancomycin resistant enterococcal infections. N Engl J Med 2000;342:710-21. 2B.42 Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000;31:586-9. 2B.43 Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect 2009;15:224-31. 2B.44 Arias CA et al. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010; 16:555-62. 2B.45 Parkash V et al. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum β-lactamases. Antimicrob Agents Chemother 2009;53:1278-80. 2B.46 Rodríguez-Baño J et al. Clinical significance of extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 2008;6:671-83. 2B.47 Paterson DL et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended beta-lactamases. Clin Infect Dis 2004;39:31-7. 2B.48 Giske CG et al. Redefining extended-spectrum β-lactamases: balancing science and clinical need. J Antimicrob Chemother 2009;63:1-4. 2B.49 Hirsch EB et al. Duration and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;65:1119-25. 2B.50 Pitout JD. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 2008;6:657-69. 2B.51 Roberts JA et al. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007;30:11-8. 2B.52 Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010;70:313-33. 2B.53 Glupczynski Y et al. In vitro activity of temocillin against prevalent extended spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 2007;26:777-83. 2B.54 Rodriguez-Villalobos H et al. In vitro activity of temocillin against extended spectrum β-lactamase producing Escherichia coli. J Antimicrob Chemother 2006;57:771-4. 2B.55 Kelesidis T et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008;62: 895-904. 2B.56 Castanheira M et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008; 52:570-3. 2B.57 Nordmann P et al. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-36. 2B.58 Briceño DF et al. Treatment options for multidrug-resistant nonfermenters. Expert Rev Anti Infect Ther 2010;8:303-15. 2B.59 Zavascki AP et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71-93. 2B.60 Mesaros N et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13:560-78. 2B.61 Jones RN et al. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY antimicrobial surveillance program (1997-2007). Diagn Microbiol Infect Dis 2009;65:331-4. 2B.62 Paul M et al. β-lactam monotherapy versus β-lactam aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br Med J 2004;328:668-81. 2B.63 Safdar N et al. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4:519-27. 2B.64 Paul M et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J 2003;326:1111-9. 2B.65 Furno P et al. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231-242. 2B.66 Paul M et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006;1:CD003344. 2B.67 Paul M et al. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect Dis Clin North Am 2009;23:277-93. 2B.68 Levin AS et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11. 2B.69 Falagas ME et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35:194-9. 2B.70 Li J et al. Colistin: the re-emerging antibiotic for multidrug-resistant, Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601. 2B.71 Falagas ME et al. Colistin: the revival of polymyxins for the management of multidrug-resistant Gramnegative bacterial infections. Clin Infect Dis 2005;40:1333-41. 2B.72 Falagas ME et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77. 2B.73 Falagas ME et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009;34:111-20. 2B.74 Drapeau CM et al. Rifampicin combined regimens for Gram-negative infections: data from the literature. Int J Antimicrob Agents 2010;35:39-44. 2B.75 Plachouras D et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6. 2B.76 Garau J et al. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol
- Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
- Page 3 and 4: 1.89 Laupland KB. Vascular and para
- Page 5 and 6: of NICE guidance. Br Med J 2008;337
- Page 7 and 8: tions à Clostridium difficile dans
- Page 9 and 10: sis of placebo-controlled trials. C
- Page 11 and 12: 1.446 Centers for Disease Control a
- Page 13 and 14: 1.532 Olaison L et al. Enterococcal
- Page 15 and 16: 1.615 Muder RR et al. Isolation of
- Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
- Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
- Page 21 and 22: 1.873 Korting HC et al. Current top
- Page 23 and 24: 1.970 Thomas RJ et al. Current mana
- Page 25 and 26: of severe respiratory failure. Clin
- Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
- Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
- Page 31: test methodology. Eur J Clin Microb
- Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
- Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
- Page 39 and 40: after acute pyelonephritis: a multi
- Page 41 and 42: for intensive care patients with no
- Page 43 and 44: among hospitalized patients. Clin I
- Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
- Page 47 and 48: 7.38 Meersseman W et al. Invasive a
- Page 49 and 50: 7.121 Walsh TJ et al. All catheter
- Page 51 and 52: nail onychomycosis. J Eur Acad Derm
- Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
- Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
- Page 57 and 58: factor and other newly approved bio
- Page 59 and 60: cument E.DEF 8.1). Report of the Su
- Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
- Page 63 and 64: new prediction equation. Ann Intern
- Page 65 and 66: 14A.93 Sundar S et al. New treatmen
- Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
- Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
- Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
- Page 73 and 74: 18.12 Panel on Antiretroviral Thera
- Page 75 and 76: 18.91 Lesho E. Evidence base for us
- Page 77 and 78: tients. J Antimicrob Chemother 2009
- Page 79 and 80: duct characteristics. Available at:
- Page 81 and 82: _Product_Information/human/000338/W
2B.3 Karageorgopoulos DE et al. Current control and treatment of multidrug-resistant Acinetobacter baumannii<br />
infections. Lancet Infect Dis 2008;8:751-62.<br />
2B.4 Zavascki AP et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance<br />
mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71-93.<br />
2A.5 Perez F et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents<br />
Chemother 2007;51:3471-84.<br />
2B.6 Munoz-Price LS et al. Acinetobacter infection. N Engl J Med 2008;358:1271-81.<br />
2B.7 Gootz TD et al. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect<br />
Ther 2008;6:309-325.<br />
2B.8 Maragakis LL et al. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment<br />
options. Clin Infect Dis 2008;46:1254-63.<br />
2B.9 Appleman MD et al. In vitro activities of non traditional antimicrobials against multiresistant Acinetobacter<br />
baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother<br />
2000;44:1035-40.<br />
2B.10 Murray CK et al. Treatment of multidrug resistant Acinetobacter. Curr Opin Infect Dis 2005;18:502-<br />
6.<br />
2B.11 Fournier PE et al. The epidemiology and control of Acinetobacter baumannii in health care facilities.<br />
Clin Infect Dis 2006;42:692-9.<br />
2B.12 Sengstock DM et al. Multidrug‐resistant Acinetobacter baumannii: an emerging pathogen among older<br />
adults in community hospitals and nursing homes. Clin Infect Dis 2010;50:1611-6.<br />
2B.13 Yoon J et al. In vitro double and triple synergistic activities of polymyxin B, imipenem and rifampin<br />
against multidrug resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:753-<br />
7.<br />
2B.14 Roberts JA et al. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role.<br />
Int J Antimicrob Agents 2007;30:11-8.<br />
2B.15 Gordon NC et al. A review of clinical and microbiological outcomes following treatment of infections<br />
involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother<br />
2009;63:775-80.<br />
2B.16 Moland ES et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii<br />
and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother 2008;52:2940-2.<br />
2B.17 Scheetz MH et al. In vitro activities of various antimicrobials alone and in combination with tigecycline<br />
against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother<br />
2007;51:1621-6.<br />
2B.18 Karageorgopoulos DE et al. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant)<br />
Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother<br />
2008;62:45-55.<br />
2B.19 Anthony KB et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant<br />
Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70.<br />
2B.20 Peleg AY et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary<br />
report. J Antimicrob Chemother 2007;59:128-31.<br />
2B.21 Capone AJ et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii. J<br />
Antimicrob Chemother 2008;62:422-5.<br />
2B.22 Navon-Venezia S et al. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J<br />
Antimicrob Chemother 2007;59:772-4.<br />
2B.23 Bassetti M et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii<br />
infections. J Antimicrob Chemother 2008;61:417-20.<br />
2B.24 Garnacho-Montero J et al. Treatment of multidrug resistant Acinetobacter baumannii ventilator associated<br />
pneumonia (VAP) with intravenous colistin: a comparison with imipenem susceptible VAP. Clin<br />
Infect Dis 2003;36:1111-8.<br />
2B.25 Levin AS et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant<br />
Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11.<br />
2B.26 Falagas ME et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative<br />
bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;<br />
35:194-9.<br />
2B.27 Li J et al. Colistin: the re-emerging antibiotic for multidrug-resistant, Gram-negative bacterial infections.<br />
Lancet Infect Dis 2006;6:589-601.<br />
2B.28 Falagas ME et al. Colistin: the revival of polymyxins for the management of multidrug-resistant Gramnegative<br />
bacterial infections. Clin Infect Dis 2005;40:1333-41.<br />
2B.29 Falagas ME et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting<br />
Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int<br />
J Antimicrob Agents 2009;34:111-20.<br />
2B.30 Drapeau CM et al. Rifampicin combined regimens for Gram-negative infections: data from the literature.<br />
Int J Antimicrob Agents 2010;35:39-44.<br />
2B.31 Plachouras D et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after<br />
intravenous administration in critically ill patients with infections caused by Gram-negative bacteria.<br />
Antimicrob Agents Chemother 2009;53:3430-6.<br />
2B.32 Giske CG et al. Redefining extended-spectrum β-lactamases: balancing science and clinical need. J<br />
Antimicrob Chemother 2009;63:1-4.<br />
2B.33 Roberts JA et al. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role.<br />
Int J Antimicrob Agents 2007;30:11-8.<br />
2B.34 Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing<br />
epidemiology and drug treatment choices. Drugs 2010;70:313-33.<br />
2B.35 Glupczynski Y et al. In vitro activity of temocillin against prevalent extended spectrum beta-lactamases<br />
producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis<br />
2007;26:777-83.<br />
2B.36 Castanheira M et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials<br />
tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report<br />
from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008;52:<br />
570-3.<br />
2B.37 Arias CA et al. Emergence and management of drug-resistant enterococcal infections. Expert Rev<br />
Anti Infect Ther 2008;6:637-55.<br />
2B.38 Gavaldà J et al. Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann<br />
Intern Med 2007;146:574-9.
Change language